← Leaderboards
Joseph Desimone
University Of Illinois At Chicago
$3,651,968
Attributed
$6,620,869
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.8M · FY2005–19$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$11,106,706 · 7
By mechanism
U54$4,485,837 · 1
U01$3,159,602 · 1
R44$1,725,000 · 1
R01$1,239,634 · 1
U10$483,957 · 1
P51$12,676 · 2
Top collaborators
- Yogen Saunthararajah5 shared
- James Douglas Engel2 shared
Most similar at University Of Illinois At Chicago
Same institution · by research overlap
- Yogen Saunthararajah$12,927,987
- Donald Lavelle$5,608,438
- Alan P. Kozikowski$10,594,236
- Guy L Weinberg$414,676
Others in their field
Top investigators on “Safety”
- David Heimbrook · Leidos Biomedical Research, Inc.$398,099,186
- Lawrence Corey · Fred Hutchinson Cancer Center$396,952,463
- Mitchell J Malone · Texas A&M Research Foundation$329,191,208
- Gary D Acton · University Of California-Davis$320,373,312
- Melynda Holmes · Technical Resources Inc$232,659,786
- Beth Baseler · Leidos Biomedical Research, Inc.$225,257,316
Research focus
SafetyPharmaceutical PreparationsClinical TrialsSickle Cell AnemiaDoseDecitabineFetal HemoglobinHydroxyureaGenesCytotoxicFunctional DisorderOralMorbidity - Disease RateHemoglobinHemolysisClinical ResearchCoagulation ProcessPlacebosModificationDrug CombinationsIn VitroIn VivoGlobinFda Approved
Grant awards (17)
A Novel, Non-Cytotoxic, Epigenetic Therapeutic for Sickle Cell Disease$750,000
R44 · FY2019 · HL · contact PI
A Novel, Non-Cytotoxic, Epigenetic Therapeutic for Sickle Cell Disease$750,000
R44 · FY2018 · HL · contact PI
A Novel, Non-Cytotoxic, Epigenetic Therapeutic for Sickle Cell Disease$225,000
R44 · FY2017 · HL · contact PI
Improving HbF induction by inhibiting epigenetic target enzymes$1,707,550
U01 · FY2014 · HL
Improving HbF induction by inhibiting epigenetic target enzymes$1,452,052
U01 · FY2013 · HL
Chicago Comprehensive Sickle Cell Center: Basic & Translational Research Program$1
U54 · FY2011 · HL · contact PI
Chicago Comprehensive Sickle Cell Center: Basic & Translational Research Program$1,823,590
U54 · FY2009 · HL · contact PI
Chicago Comprehensive Sickle Cell Center: Basic & Translational Research Program$2,662,246
U54 · FY2008 · HL · contact PI
Chicago Sickle Cell Clinical Network$170,651
U10 · FY2008 · HL · contact PI
Chicago Sickle Cell Clinical Network$147,651
U10 · FY2007 · HL · contact PI
DNA Methylation, Chromatin, and Globin Gene Silencing$304,414
R01 · FY2006 · HL · contact PI
Chicago Sickle Cell Clinical Network$165,655
U10 · FY2006 · HL · contact PI
DNA METHYLATION, CHROMATIN AND GLOBIN GENE SILENCING$7,014
P51 · FY2006 · RR · contact PI
DNA Methylation, Chromatin, and Globin Gene Silencing$311,740
R01 · FY2005 · HL
DNA METHYLATION, CHROMATIN AND GLOBIN GENE SILENCING$5,662
P51 · FY2005 · RR
DNA Methylation, Chromatin, and Globin Gene Silencing$311,740
R01 · FY2004 · HL
DNA Methylation, Chromatin, and Globin Gene Silencing$311,740
R01 · FY2003 · HL